生物技术公司Aktis Oncology宣布，其研发的靶向Nectin-4的微型蛋白放射性偶联物AKY-1189，已获得美国食品药品监督管理局（FDA）授予的快速通道资格。这一认定将加速该候选药物的临床开发及审评进程，为晚期实体瘤患者提供新的治疗希望。
生物技术公司Aktis Oncology宣布，其研发的靶向Nectin-4的微型蛋白放射性偶联物AKY-1189，已获得美国食品药品监督管理局（FDA）授予的快速通道资格。这一认定将加速该候选药物的临床开发及审评进程，为晚期实体瘤患者提供新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.